S&P 500   5,255.31 (+0.13%)
DOW   39,786.30 (+0.07%)
QQQ   445.52 (+0.16%)
AAPL   171.23 (-1.20%)
MSFT   420.96 (-0.11%)
META   489.18 (-0.95%)
GOOGL   150.88 (+0.01%)
AMZN   180.63 (+0.44%)
TSLA   177.44 (-1.33%)
NVDA   908.62 (+0.68%)
NIO   4.70 (+0.64%)
AMD   181.47 (+1.05%)
BABA   72.30 (+0.99%)
T   17.61 (+0.34%)
F   13.22 (+1.23%)
MU   118.98 (-0.13%)
CGC   8.91 (-6.70%)
GE   177.09 (-1.68%)
DIS   122.56 (+1.31%)
AMC   3.83 (-11.75%)
PFE   27.87 (+0.32%)
PYPL   66.77 (+0.30%)
XOM   115.34 (+0.32%)
S&P 500   5,255.31 (+0.13%)
DOW   39,786.30 (+0.07%)
QQQ   445.52 (+0.16%)
AAPL   171.23 (-1.20%)
MSFT   420.96 (-0.11%)
META   489.18 (-0.95%)
GOOGL   150.88 (+0.01%)
AMZN   180.63 (+0.44%)
TSLA   177.44 (-1.33%)
NVDA   908.62 (+0.68%)
NIO   4.70 (+0.64%)
AMD   181.47 (+1.05%)
BABA   72.30 (+0.99%)
T   17.61 (+0.34%)
F   13.22 (+1.23%)
MU   118.98 (-0.13%)
CGC   8.91 (-6.70%)
GE   177.09 (-1.68%)
DIS   122.56 (+1.31%)
AMC   3.83 (-11.75%)
PFE   27.87 (+0.32%)
PYPL   66.77 (+0.30%)
XOM   115.34 (+0.32%)
S&P 500   5,255.31 (+0.13%)
DOW   39,786.30 (+0.07%)
QQQ   445.52 (+0.16%)
AAPL   171.23 (-1.20%)
MSFT   420.96 (-0.11%)
META   489.18 (-0.95%)
GOOGL   150.88 (+0.01%)
AMZN   180.63 (+0.44%)
TSLA   177.44 (-1.33%)
NVDA   908.62 (+0.68%)
NIO   4.70 (+0.64%)
AMD   181.47 (+1.05%)
BABA   72.30 (+0.99%)
T   17.61 (+0.34%)
F   13.22 (+1.23%)
MU   118.98 (-0.13%)
CGC   8.91 (-6.70%)
GE   177.09 (-1.68%)
DIS   122.56 (+1.31%)
AMC   3.83 (-11.75%)
PFE   27.87 (+0.32%)
PYPL   66.77 (+0.30%)
XOM   115.34 (+0.32%)
S&P 500   5,255.31 (+0.13%)
DOW   39,786.30 (+0.07%)
QQQ   445.52 (+0.16%)
AAPL   171.23 (-1.20%)
MSFT   420.96 (-0.11%)
META   489.18 (-0.95%)
GOOGL   150.88 (+0.01%)
AMZN   180.63 (+0.44%)
TSLA   177.44 (-1.33%)
NVDA   908.62 (+0.68%)
NIO   4.70 (+0.64%)
AMD   181.47 (+1.05%)
BABA   72.30 (+0.99%)
T   17.61 (+0.34%)
F   13.22 (+1.23%)
MU   118.98 (-0.13%)
CGC   8.91 (-6.70%)
GE   177.09 (-1.68%)
DIS   122.56 (+1.31%)
AMC   3.83 (-11.75%)
PFE   27.87 (+0.32%)
PYPL   66.77 (+0.30%)
XOM   115.34 (+0.32%)

TScan Therapeutics (TCRX) Stock Price, News & Analysis

$8.15
-0.15 (-1.81%)
(As of 09:52 AM ET)
Today's Range
$7.28
$8.27
50-Day Range
$4.89
$8.30
52-Week Range
$1.62
$9.00
Volume
42,405 shs
Average Volume
162,615 shs
Market Capitalization
$390.22 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.50

TScan Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
56.8% Upside
$12.50 Price Target
Short Interest
Healthy
0.52% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.61mentions of TScan Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.18) to ($1.13) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.39 out of 5 stars

Medical Sector

531st out of 939 stocks

Biological Products, Except Diagnostic Industry

87th out of 156 stocks

TCRX stock logo

About TScan Therapeutics Stock (NASDAQ:TCRX)

TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 that is in Phase I of clinical trial for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-204 that is in Phase I for the treatment of solid tumors. The company also developing TSC-200, TSC-201, TSC-202, TSC-203, and TSC-205 for the treatment of solid tumors. In addition, it engages in the developing vaccines for infectious diseases, such as SARS-CoV-2. The company has a collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc., to identify novel cancer antigens from the T cells of patients with a certain specific type of cancer; and a collaboration agreement with Amgen to identify novel targets in Crohn's disease. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

TCRX Stock Price History

TCRX Stock News Headlines

CBOE shift unlocks new weekend income strategy
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. You're probably wondering, “Okay… But how does that affect me?” This perk now allows everyday traders like yourself to target extra income over the weekend.
TScan Therapeutics: Q4 Earnings Insights
The AI Defense Stock Set to Soar
To protect our interests, The Pentagon has partnered with this small AI defense contractor - creating some of the most powerful AI defenses ever made.
TScan Appoints Jason Amello As CFO
TScan Therapeutics appoints CFO
See More Headlines
Receive TCRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for TScan Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/06/2024
Today
3/28/2024
Next Earnings (Estimated)
5/08/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:TCRX
Fax
N/A
Employees
154
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$12.50
High Stock Price Target
$15.00
Low Stock Price Target
$10.00
Potential Upside/Downside
+56.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-89,220,000.00
Net Margins
-423.86%
Pretax Margin
-423.86%

Debt

Sales & Book Value

Annual Sales
$21.05 million
Book Value
$3.15 per share

Miscellaneous

Free Float
43,922,000
Market Cap
$381.60 million
Optionable
Not Optionable
Beta
0.87
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Dr. Gavin MacBeath Ph.D. (Age 54)
    CEO & Director
    Comp: $650.17k
  • Dr. Stephen J. Elledge Ph.D.
    Co-Founder & Chairman of Scientific Advisory Board
  • Mr. Tomasz Kula Ph.D.
    Co-Founder & Member of Advisory Board
  • Mr. Jason A. Amello (Age 56)
    Chief Financial Officer
  • Mr. Leiden Dworak M.B.A.
    Principal Accounting Officer & Treasurer
  • Dr. Justin McCue Ph.D.
    Chief Technology Officer
  • Dr. Zoran Zdraveski J.D. (Age 53)
    Ph.D., Chief Legal & Strategy Officer and Company Secretary
  • Ms. Ann Hargraves
    Senior Vice President of Human Resources
  • Dr. Shrikanta Chattopadhyay M.D.
    Senior VP & Head of Translational Medicine
  • Dr. Debora Barton M.D. (Age 48)
    Chief Medical Officer

TCRX Stock Analysis - Frequently Asked Questions

Should I buy or sell TScan Therapeutics stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for TScan Therapeutics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" TCRX shares.
View TCRX analyst ratings
or view top-rated stocks.

What is TScan Therapeutics' stock price target for 2024?

3 brokerages have issued 1 year price objectives for TScan Therapeutics' stock. Their TCRX share price targets range from $10.00 to $15.00. On average, they expect the company's share price to reach $12.50 in the next twelve months. This suggests a possible upside of 56.8% from the stock's current price.
View analysts price targets for TCRX
or view top-rated stocks among Wall Street analysts.

How have TCRX shares performed in 2024?

TScan Therapeutics' stock was trading at $5.83 at the start of the year. Since then, TCRX stock has increased by 36.7% and is now trading at $7.97.
View the best growth stocks for 2024 here
.

When is TScan Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our TCRX earnings forecast
.

How were TScan Therapeutics' earnings last quarter?

TScan Therapeutics, Inc. (NASDAQ:TCRX) posted its earnings results on Wednesday, March, 6th. The company reported ($0.21) EPS for the quarter, topping the consensus estimate of ($0.29) by $0.08. The firm had revenue of $7.21 million for the quarter, compared to analysts' expectations of $2.94 million. TScan Therapeutics had a negative trailing twelve-month return on equity of 60.65% and a negative net margin of 423.86%.

What ETF holds TScan Therapeutics' stock?

Simplify Propel Opportunities ETF holds 1,046,916 shares of TCRX stock, representing 2.20% of its portfolio.

When did TScan Therapeutics IPO?

TScan Therapeutics (TCRX) raised $100 million in an IPO on Friday, July 16th 2021. The company issued 6,250,000 shares at $15.00-$17.00 per share.

Who are TScan Therapeutics' major shareholders?

TScan Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (3.74%), Vanguard Group Inc. (3.74%), abrdn plc (0.42%), Stifel Financial Corp (0.25%), Balyasny Asset Management L.P. (0.10%) and Goldman Sachs Group Inc. (0.06%). Insiders that own company stock include Barbara Klencke, Brian M Silver, David P Southwell, Gavin Macbeath, Lynx1 Capital Management Lp, Timothy J Barberich and Zoran Zdraveski.
View institutional ownership trends
.

How do I buy shares of TScan Therapeutics?

Shares of TCRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:TCRX) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners